Molecular Mechanisms And Their Clinical Application In Malignancies

Molecular Mechanisms and their Clinical Application in Malignancies is a collection of manuscripts presented at the 12th Annual Bristol-Myers Squibb Symposium on Cancer Research, held in Toronto, Canada on September 26-27, 1989. This symposium reviews the current understanding of the mechanisms of malignant transformation and the application of several technologies to the diagnosis, evaluation, and treatment of malignancies. This book is divided into 14 chapters. The opening chapters deal with the genetic basis of neoplasia and the molecular biology of oncogenes, the regulation of transcription, and the rearrangement of T- and B-cell genes during development and in malignancies. The subsequent chapters focus on the genetic abnormalities detected in specific tumors, such as retinoblastoma, colorectal carcinoma, and lung cancer. These chapters also examine the retinoid and thyroid hormone receptors. Other chapters explore the genetic basis of the cellular response to therapy, drug resistance, cachectin-tumor necrosis factor in the biology of disease, acute myelogenous leukemia, and the stages in tumor progression. The final chapters look into the application of molecular biology to clinical treatment in the form of receptor specific intoxication on tumor cells, the molecular genetic analysis of the phakomycoses, and the structural design of antitumor compounds. This book will prove useful to oncologists, molecular biologists, clinicians, and researchers.

This book describes molecular processes whose deregulation is important in the formation of tumors. The material is developed from basic cell signaling pathways to their roles in the clinical manifestation of specific cancers. Topics covered include molecular events intrinsic to tumor cells (leading to growth deregulation, extended lifespan, and the ability to invade surrounding tissue), protective mechanisms that prevent transformation (including DNA repair and epigenetic regulation), tumor-host interactions (with the endocrine system, the immune system, and blood vessel formation), and the underlying molecular defects of individual cancers.

Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital – Azienda Sanitaria Locale 21 of the Veneto Region – and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.

Cancer is a major public health problem and much research is being conducted to develop effective treatments for various types of malignancies. In doing so, researchers must have comprehensive knowledge about what causes cancer. This book explains the mechanisms of different types of cancers in twelve chapters organized into three sections on oncogenes, tumor suppressor genes, and viral oncogenes.

The WHO report estimates that 12 million people will be diagnosed with some form of cancer this year. In addition, the report predicts that more than 7 million people will die early from the disease. Together, the number of cancer cases and deaths from cancer are expected to increase by one percent each year. Cancer research has seen remarkable advancements, including the multi-step carcinogenesis theory and the identification of a cancer stem cell. These advancements are being applied to clinical therapies targeting the oncogne. In addition, the function of the gene product is becoming clear through analysis of the intracellular signaling of the oncogene. As a result, it has become clear that the morphologies of the cancers depend on the kind of the abnormal gene. of course, these differences would influence patient's life and death and is summarized by specialists in this area. This theme includes the full range of human diseases regarding medical genetics, biochemistry, microbiology, immunology, anatomy, pathology, structural biology, molecular cell biology, neuroscience and developmental biology. the Ebook contains articles written by specialists in this area. It should prove to be of great use to clinicians and scientists in all medical fields.

The Molecular Biology of Cancer, Stella Pelengaris & Michael Khan This capturing, comprehensive text, extensively revised and updated for its second edition, provides a detailed overview of the molecular mechanisms underpinning the development of cancer and its treatment. “Bench to Bedside”: A key strength of this book that sets it apart from general cancer biology references is the interweaving of all aspects of cancer biology from the causes, development and diagnosis through to the treatment and care of cancer patients – essential for providing a broader view of cancer and its impact. The highly readable presentation of a complex field, written by an international panel of researchers, specialists and practitioners, would provide an excellent text for graduate and undergraduate courses in the biology of cancer, medical students and qualified practitioners in the field preparing for higher exams, and for researchers and teachers in the field. For the teaching of cancer biology, special features have been included to facilitate this use: bullet points at the beginning of each chapter explaining key concepts and controversial areas; each chapter builds on concepts learned in previous chapters, with a list of key outstanding questions remaining in the field, suggestions for further reading, and questions for student review. All chapters contain text boxes that provide additional and relevant information. Key highlights are listed below: An overview of the cancer cell and important new concepts. Selected human cancers: lung, breast, colorectal, prostate, renal, skin, cervix, and hematological malignancies. Key cellular processes in cancer biology including (a) traditionally important areas such as cell cycle control, growth regulation, oncogenes and tumour suppressors apoptosis, as well as (b) more highly topical areas of apoptosis, telomeres, DNA damage and repair, cell adhesion, angiogenesis, immunity, epigenetics, and the proteasome. Clinical oncology: In-depth coverage of important concepts such as screening, risk of cancer and prevention, diagnoses, managing cancer patients from start to palliative care and end-of-life pathways. Chapters highlighting the direct links between cancer research and clinical applications. New coverage on how cancer drugs are actually used in specific cancer patients, and how therapies are developed and tested. Systems Biology and cutting edge research areas covered such as RNA interference (RNAi). Each chapter includes key points, chapter summaries, text boxes, and topical references for added comprehension and review. Quotations have been used in each chapter to introduce basic concepts in an entertaining way. Supported by a dedicated website at www.blackwellpublishing.com/pelengaris We should list the great reviews we got for first edition which are on the back of the 2nd edition: “A capturing, comprehensive, clearly written and absolutely accurate introduction into cancer biology…..This book deserves great praise for the readable presentation of this complex field….the true synthesis of bench and bedside approaches is marvelously achieved.” Christian Schmidt, Molecular Cell “Chapters address the issues of cancer diagnosis, treatment, and patient care and set the book apart from general molecular biology references….This book is applicable to both graduate and undergraduate students, and in the context of a research laboratory, this book would be an excellent resource as a reference guide for scientists at all levels.” V.Emuss, Institute of Cancer Research, London. Also, from the first edition: “Pelengaris, Khan, and the contributing authors are to be applauded. The Molecular Biology of Cancer is a comprehensive and readable presentation of the many faces of cancer from molecular mechanisms to clinical therapies and diagnostics. This book will be welcomed by neophyte students, established scientists in other fields, and curious physicians.” -Dean Felsher, Stanford University